Caffeine - Adverse effects
Research News and Information

Saturday, November 21, 2009

Caffeine's implications for women's health and survey of obstetrician-gynecologists' caffeine knowledge and assessment practices.

30 Aug 2009 OBJECTIVE: Caffeine has relevance for women's health and pregnancy, including significant associations with spontaneous abortion and low birth weight. According to scientific data, pregnant women and women of reproductive age should be advised to ... Read more...

Caffeine expectancy: instrument development in the Rasch measurement framework.

30 Aug 2009 Although caffeine is the most widely consumed psychoactive drug in the world, the mechanisms associated with consumption are not well understood. Nonetheless, outcome expectancies for caffeine use are thought to underlie caffeine's reinforcing ... Read more...

Panic disorder and social anxiety disorder subtypes in a caffeine challenge test.

18 Aug 2009 Studies have demonstrated the vulnerability of anxiety disorder patients to challenge tests. Our aim was to observe if panic disorder (PD) patients and generalized social anxiety disorder (GSAD) and performance social anxiety disorder (PSAD) ... Read more...

Latest indexed articles for 'Caffeine - Adverse effects'

These are the very latest articles for this heading:

• Caffeine's implications for women's health and survey of obstetrician-gynecologists' caffeine knowledge and assessment practices. 30 Aug 2009
• Caffeine expectancy: instrument development in the Rasch measurement framework. 30 Aug 2009
• Panic disorder and social anxiety disorder subtypes in a caffeine challenge test. 18 Aug 2009
• Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. 2 Aug 2009
• Mountain Dew or mountain don't?: a pilot investigation of caffeine use parameters and relations to depression and anxiety symptoms in 5th- and 10th-grade students. 30 Jul 2009
• Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. 13 Jul 2009
• "Hey, doc, is it OK for me to drink coffee?". 29 Jun 2009
• Impact of serum caffeine monitoring on adverse effects and chemotherapeutic responses to caffeine-potentiated chemotherapy for osteosarcoma. 3 Jun 2009
• [Red Bull energy drink, a year later: nothing to report] Jun 2009
• What predicts the change from episodic to chronic migraine? 30 May 2009
• Caffeine in pregnancy: a cause for concern? 20 May 2009
• Fasting headache: a review of the literature and new hypotheses. 29 Apr 2009
• Caffeinated and alcoholic beverage intake in relation to ovulatory disorder infertility. 29 Apr 2009
• Caffeine-withdrawal headache induced by hemodialysis. 13 Apr 2009
• Maternal consumption of coffee and caffeine-containing beverages and oral clefts: a population-based case-control study in Norway. 31 Mar 2009
• High dietary caffeine consumption is associated with a modest increase in headache prevalence: results from the Head-HUNT Study. 22 Mar 2009
• Reciprocal roles between caffeine and estrogen on bone via differently regulating cAMP/PKA pathway: the possible mechanism for caffeine-induced osteoporosis in women and estrogen's antagonistic effects. 8 Mar 2009
• Relationship between long-term coffee consumption and components of the metabolic syndrome: the Amsterdam Growth and Health Longitudinal Study. 8 Mar 2009
• Coffee consumption and risk of cardiovascular events and all-cause mortality among women with type 2 diabetes. 4 Mar 2009
• A case of ventricular tachycardia related to caffeine pretreatment. 27 Feb 2009

See a longer list of these articles.

Technical information about 'Caffeine'

Definition: A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes SMOOTH MUSCLE, stimulates CARDIAC MUSCLE, stimulates DIURESIS, and appears to be useful in the treatment of some types of headache. Several cellular actions of caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide PHOSPHODIESTERASES, antagonism of ADENOSINE RECEPTORS, and modulation of intracellular calcium handling.

Chemical name: 1H-Purine-2,6-dione, 3,7-dihydro-1,3,7-trimethyl-

Registry Number: 58-08-2

Descriptor UI: D002110

Alternative terms: Caffeine; 1,3,7-Trimethylxanthine; Coffeinum N; Merck dura Brand of Caffeine; Coffeinum Purrum; Berlin-Chemie Brand of Caffeine; Dexitac; Republic Drug Brand of Caffeine; Vivarin; GlaxoSmithKline Brand of Caffeine; No Doz; Bristol-Myers Squibb Brand of Caffeine; Percoffedrinol N; Passauer Brand of Caffeine; Percutaféine; Pierre Fabre Brand of Caffeine; Quick-Pep; Thompson Brand 2 of Caffeine; Caffedrine; Thompson Brand 1 of Caffeine; Durvitan; Seid Brand of Caffeine;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Phosphodiesterase Inhibitors; Central Nervous System Stimulants;

Tree Number: D03.132.960.175; D03.438.759.758.824.175;